Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 14 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 16 May 2016 Planned End Date changed from 1 May 2016 to 1 Jan 2020.
- 11 Apr 2016 Planned End Date changed from 1 Jan 2020 to 1 May 2016.